<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-611
Date of Submission: 2025-05-16

This report was submitted by a Other Healthcare Professional from Park-Harrington Medical Center concerning patient ANON-PX-5346. The subject is an adult female with a significant medical history including osteoarthritis, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 144mg, initiated on 2025-03-05 for Pain and inflammation with the course ongoing; Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 174mg, initiated on 2025-03-05 for Hypertension with the course ongoing.

On approximately 2025-03-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Nausea. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed structure and advised Mr. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed left and advised study. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Because score possible they data movement. Dream capital service. Option small trial which blood hour.</data>
report_id: ADR-2025-611
report_date: '2025-05-16'
patient_details:
  patient_id: ANON-PX-5346
  gender: Female
  relevant_history:
  - osteoarthritis
  - coronary artery disease
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 144mg
  route_of_administration: Oral
  start_date: '2025-03-05'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
- drug_name: Lisinopril
  dosage: 174mg
  route_of_administration: Oral
  start_date: '2025-03-05'
  indication_for_use: Hypertension
  drug_class: ACE inhibitor
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2025-03-23'
  severity: Mild
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed structure and advised Mr.
- symptom_name: Nausea
  onset_date: '2025-03-23'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed left and advised study.
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 9
reporting_facility: Park-Harrington Medical Center
reporter_type: Other Healthcare Professional
notes: Because score possible they data movement. Dream capital service. Option small
  trial which blood hour.
